Nicotinic Acid - Pharmacokinetics, Pharmacodynamics, Receptor Expression

Summary

The study will be a double-blind, randomized, placebo-controlled, single-center, 2 treatment, 3--way crossover. Subjects will be randomly allocated to a treatment sequence - AAB, ABA or BAA. The two treatments will be: * Treatment A: 500 mg nicotinic acid (Niacor(R)) * Treatment B: Niacor(R) Placebo Each trial period will last one day, there will be a wash-out period of at least 2 days between each trial period. Five to seven days after study day 1 of trial period 3 there will be a final safety examination.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications

No indication recorded.